Aviir/ P&P enter distribution agreement covering 19 Middle Eastern and North African countries

Aviir has signed an agreement with Partners & Partners (P&P), under which P&P will form the sole distributorship of Aviir testing products and technologies in 19 Middle Eastern and North African countries. Through its affiliate, Qatar Heart Laboratory, P&P intends to launch, country-by-country, a network that will distribute and promote Aviir tests, including the Aviir MIRISK VP assessment. The agreement follows a US$10 million financing tranche for Aviir, which included participation by the company's current investor group, along with P&P.

Under the agreement, P&P will have the exclusive rights to set up diagnostic laboratories across the region, including Qatar, UAE, Saudi Arabia, Kuwait, Oman, Turkey, Egypt, Morocco and 12 other countries. The lab tests will be performed either on site using both commercially available and Aviir technology, or samples will be shipped to Aviir’s Irvine, CA laboratory for analysis and turnaround.

Aviir’s proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high-risk of experiencing a cardiac event over the next five years. The MIRISK VP technology measures the blood levels of seven proteins associated with the development of vulnerable plaque. It then uses a complex algorithm to analyse those results and other known risk factors to determine an individual's probability of experiencing a myocardial infarction within the next five years.

Aviir/ P&P enter distribution agreement covering 19 Middle Eastern and North African countries

Aviir has signed an agreement with Partners & Partners (P&P), under which P&P will form the sole distributorship of Aviir testing products and technologies in 19 Middle Eastern and North African countries. Through its affiliate, Qatar Heart Laboratory, P&P intends to launch, country-by-country, a network that will distribute and promote Aviir tests, including the Aviir MIRISK VP assessment. The agreement follows a US$10 million financing tranche for Aviir, which included participation by the company's current investor group, along with P&P.

Under the agreement, P&P will have the exclusive rights to set up diagnostic laboratories across the region, including Qatar, UAE, Saudi Arabia, Kuwait, Oman, Turkey, Egypt, Morocco and 12 other countries. The lab tests will be performed either on site using both commercially available and Aviir technology, or samples will be shipped to Aviir’s Irvine, CA laboratory for analysis and turnaround.

Aviir’s proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high-risk of experiencing a cardiac event over the next five years. The MIRISK VP technology measures the blood levels of seven proteins associated with the development of vulnerable plaque. It then uses a complex algorithm to analyse those results and other known risk factors to determine an individual's probability of experiencing a myocardial infarction within the next five years.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.